Original Publication Date: >14 August, 2015
Publication / Source: Future Neurology
Authors: Andrea J Lindahl & Douglas G MacMahon
The introduction of dopamine agonists was a welcome development in the treatment of Parkinson’s disease. However, their history has been somewhat checkered with concerns about their side effects including sudden onset of sleep and ‘sleep attacks’ the development of fibrotic side effects with ergot-derived agents; and most recently, the emergence of impulse control disorders.